{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:23:50Z","timestamp":1783041830524,"version":"3.54.6"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.neuropharm.2021.108586","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T02:22:38Z","timestamp":1619835758000},"page":"108586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-1917","authenticated-orcid":false,"given":"Anne Katrin","family":"Schlag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoirse E.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan R.","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108586_bib69","unstructured":"Alta Flora, 2020. Two years on- what does the data say? https:\/\/alta-flora.com\/en\/blog\/two-years-on-what-does-the-data-say\/ [accessed May 5th 2021]."},{"key":"10.1016\/j.neuropharm.2021.108586_bib1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems\u2014a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.neuropharm.2021.108586_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108586_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(98)00392-6","article-title":"An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity","volume":"353","author":"Ben-Shabat","year":"1998","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108586_bib5","article-title":"Medicinal cannabis for inflammatory bowel disease: a survey of perspectives, experiences, and current use in Australian patients","volume":"2","author":"Benson","year":"2020","journal-title":"Crohn\u2019s Colitis 360"},{"key":"10.1016\/j.neuropharm.2021.108586_bib62","author":"Bfarm"},{"key":"10.1016\/j.neuropharm.2021.108586_bib6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2021.108586_bib7","series-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","author":"Blessing","year":"2015"},{"key":"10.1016\/j.neuropharm.2021.108586_bib67","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jpain.2016.03.002","article-title":"Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain","volume":"17","author":"Boehnke","year":"2016","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2021.108586_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/JCP.0000000000000129","article-title":"Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis","volume":"34","author":"Brunt","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbi.2020.04.079","article-title":"SARS-CoV2 induced respiratory distress: can cannabinoids be added to anti-viral therapies to reduce lung inflammation?","volume":"87","author":"Byrareddy","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2021.108586_bib10","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/pm\/pnaa303","article-title":"Ingestion of a THC-rich cannabis oil in people with Fibromyalgia: a randomized, double-blind, placebo-controlled clinical trial","volume":"21","author":"Chaves","year":"2020","journal-title":"Pain Med."},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108586_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17512433.2020.1721281","article-title":"The \u2018entourage effect\u2019 or \u2018hodge-podge hashish\u2019: the questionable rebranding, marketing, and expectations of cannabis polypharmacy","volume":"13","author":"Cogan","year":"2020","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2021.108586_bib13","author":"Costiniuk"},{"key":"10.1016\/j.neuropharm.2021.108586_bib14","series-title":"Left behind: the Scale of Illegal Cannabis Use for Medicinal Intent in the UK","author":"Couch","year":"2020"},{"key":"10.1016\/j.neuropharm.2021.108586_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/acm.2018.0437","article-title":"Cannabidiol in the treatment of post-traumatic stress disorder: a case series","volume":"25","author":"Elms","year":"2019","journal-title":"J. Alternative Compl. Med."},{"key":"10.1016\/j.neuropharm.2021.108586_bib16","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1111\/bph.15157","article-title":"The potential of cannabidiol in the COVID-19 pandemic","volume":"177","author":"Esposito","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"The Lancet Psychiatry"},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108586_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci10090572","article-title":"Cannabinoids for people with asd: a systematic review of published and ongoing studies","volume":"10","author":"Fusar-Poli","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2021.108586_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41386-020-00885-4","article-title":"Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of PPAR\u03b1 and PPAR\u03b3: repurposing a FDA-approved food additive for cocaine use disorder","volume":"46","author":"Galaj","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108586_bib20","article-title":"Medical cannabis for the treatment of Fibromyalgia","volume":"24","author":"Habib","year":"2018","journal-title":"JCR J. Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108586_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ejp.1297","article-title":"European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management","volume":"22","author":"H\u00e4user","year":"2018","journal-title":"Eur. J. Pain"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108586_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/15504263.2019.1652380","article-title":"The effectiveness of cannabinoids in the treatment of posttraumatic stress disorder (PTSD): a systematic review","volume":"16","author":"Hindocha","year":"2020","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.neuropharm.2021.108586_bib23","series-title":"Presidential Task Force on Cannabis and Cannabinoid Analgesia Position Statement","year":"2021"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108586_bib24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.euroneuro.2018.12.014","article-title":"A systematic review of phytocannabinoid exposure on the endocannabinoid system: implications for psychosis","volume":"29","author":"Jacobson","year":"2019","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2021.108586_bib25","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc16-0650","article-title":"Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study","volume":"39","author":"Jadoon","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108586_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.neuropharm.2021.108586_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/can.2020.0043","article-title":"Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA","volume":"5","author":"Khodadadi","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.neuropharm.2021.108586_bib70","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of \u03949-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20977","article-title":"Self-reported cannabidiol (CBD) use for conditions with proven therapies","volume":"3","author":"Leas","year":"2020","journal-title":"JAMA Netw. open"},{"key":"10.1016\/j.neuropharm.2021.108586_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0043-122240","article-title":"Pharmacological foundations of cannabis chemovars","volume":"84","author":"Lewis","year":"2018","journal-title":"Planta Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108586_bib30","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/pm\/pny176","article-title":"Restored self: a phenomenological study of pain relief by cannabis","volume":"20","author":"Lavie-Ajayi","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/j.neuropharm.2021.108586_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s42238-020-00038-w","article-title":"Medical cannabis use in the United States: a retrospective database study","volume":"2","author":"Mahabir","year":"2020","journal-title":"J. Cannabis Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108586_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108586_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1039\/a703973e","article-title":"From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis","volume":"16","author":"Mechoulam","year":"1999","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.neuropharm.2021.108586_bib63","unstructured":"Minnesota Department of Health 2020. Medical Cannabis Programm Update. https:\/\/www.health.state.mn.us\/people\/cannabis\/docs\/about\/quarupdates\/oct2020.pdf [accessed May 5th 2021]."},{"key":"10.1016\/j.neuropharm.2021.108586_bib65","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/MEG.0000000000001565","article-title":"Medical cannabis for inflammatory bowel disease: Real-life experience of mode of consumption and assessment of side-effects","volume":"31","author":"Naftali","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24173031","article-title":"Terpenoids and phytocannabinoids co-produced in cannabis sativa strains show specific interaction for ell cytotoxic activity","volume":"24","author":"Namdar","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2021.108586_bib61","series-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","year":"2017"},{"key":"10.1016\/j.neuropharm.2021.108586_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038687","article-title":"So near yet so far: why won't the UK prescribe medical cannabis?","volume":"10","author":"Nutt","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2021.108586_bib36","article-title":"A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products","author":"Nutt","year":"2021","journal-title":"Cannabis Cannabinoid Res"},{"issue":"123","key":"10.1016\/j.neuropharm.2021.108586_bib37","first-page":"1","article-title":"On the preparations of the Indian hemp, or gunjah, (cannabis indica)","volume":"5","author":"O'Shaughnessy","year":"1843","journal-title":"Prov Med J Retrosp Med Sci"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108586_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/can.2020.0102","article-title":"Could cannabidiol Be a treatment for coronavirus disease-19-related anxiety disorders?","volume":"6","author":"O\u2019Sullivan","year":"2020","journal-title":"Cannabis Cannabinoid Res. Online First"},{"key":"10.1016\/j.neuropharm.2021.108586_bib59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3389\/fneur.2018.00759","article-title":"Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: Observational data meta-analysis","volume":"9","author":"Pamplona","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819870977","article-title":"Insights into the role of cannabis in the management of inflammatory bowel disease","volume":"12","author":"Picardo","year":"2019","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/can.2017.0012","article-title":"Cannabis as a substitute for opioid-based pain medication: patient self-report","volume":"2","author":"Reiman","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.neuropharm.2021.108586_bib58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(02)18723-X","article-title":"On the therapeutical uses and toxic effects of Cannabis Indica","volume":"135","author":"Reynolds","year":"1890","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2021.108586_bib42","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s00213-018-5034-1","article-title":"Effect of cannabidiolic acid and \u03949-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain","volume":"235","author":"Rock","year":"2018","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108586_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0376-8716(94)90160-0","article-title":"Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms","volume":"34","author":"Rose","year":"1994","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2021.108586_bib44","doi-asserted-by":"crossref","first-page":"12869","DOI":"10.1111\/jcmm.15883","article-title":"Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome","volume":"24","author":"Salles","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2021.108586_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00226","article-title":"Single and synergistic effects of cannabidiol and \u03b4-9-tetrahydrocannabinol on zebrafish models of neuro-hyperactivity","volume":"10","author":"Samarut","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108586_bib46","first-page":"165","article-title":"Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of \u03949-THC at human CB1and CB2 receptors","volume":"4","author":"Santiago","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.neuropharm.2021.108586_bib72","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00103-019-02968-0","article-title":"Begleiterhebung zur Anwendung von Cannabisarzneimitteln in Deutschland \u2013 Zwischenauswertung","volume":"62","author":"Schmidt-Wolf","year":"2019","journal-title":"Bundesgesundheitsblatt - Gesundheitsforsch. - Gesundheitsschutz"},{"key":"10.1016\/j.neuropharm.2021.108586_bib47","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1007\/s12035-019-1637-8","article-title":"Efficacy of cannabinoids in a pre-clinical drug-screening platform for Alzheimer's disease","volume":"56","author":"Schubert","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/can.2016.0007","article-title":"A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy","volume":"1","author":"Sexton","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.neuropharm.2021.108586_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial","volume":"3","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.neuropharm.2021.108586_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-39462-1","article-title":"The association between cannabis product characteristics and symptom relief","volume":"9","author":"Stith","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2021.108586_bib51","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108586_bib66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/can.2019.0039","article-title":"The impact of medical cannabis on intermittent and chronic opioid users with back pain: How cannabis diminished prescription opioid usage","volume":"5","author":"Takakuwa","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.neuropharm.2021.108586_bib52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/JPR.S192174","article-title":"Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry","volume":"12","author":"Ueberall","year":"2019","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2021.108586_bib68","unstructured":"United Patients' Alliance (UPA) 2018. Patient Survey. https:\/\/www.upalliance.org [accessed May 1st 2020]."},{"key":"10.1016\/j.neuropharm.2021.108586_bib53","author":"Wang"},{"key":"10.1016\/j.neuropharm.2021.108586_bib54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1742-1241.2004.00271.x","article-title":"The medicinal use of cannabis in the UK: results of a nationwide survey","volume":"59","author":"Ware","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2021.108586_bib55","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jpain.2015.07.014","article-title":"Cannabis for the management of pain: assessment of safety study (COMPASS)","volume":"16","author":"Ware","year":"2015","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2021.108586_bib60","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: A systematic review and metaanalysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA - J. Am. Med. Assoc."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108586_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/can.2018.0022","article-title":"Emerging evidence for cannabis\u2019 role in opioid use disorder","volume":"3","author":"Wiese","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.neuropharm.2021.108586_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.archoralbio.2019.05.028","article-title":"Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain","volume":"104","author":"Wong","year":"2019","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.neuropharm.2021.108586_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2050324520974487","article-title":"Ending the pain of children with severe epilepsy? An audit of the impact of medical cannabis in ten patients","volume":"6","author":"Zafar","year":"2020","journal-title":"Drug Sci. Policy Law."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:11:02Z","timestamp":1758438662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":69,"alternative-id":["S0028390821001404"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108586","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108586"}}